March 3, 2026Open Access

Outcomes of durable versus biodegradable polymer drug-eluting stents in patients with coronary artery disease

CSChristof SkosMedical University of Vienna JRJovan RogozarskiMedical University of Vienna ADAl Medina DizdarevicMedical University of Vienna

Key Result

Biodegradable polymer drug-eluting stents (BP-DES) showed similar long-term MACE risk but lower target lesion revascularization compared to durable polymer DES in ACS patients.

Key Points

Durable polymer drug-eluting stents show a lower risk of target lesion revascularization in coronary artery disease patients.
Patients receiving biodegradable polymer stents experience similar long-term safety regarding major adverse cardiac events as those with durable stents.
This comparison involved assessing outcomes from stenting methods across various patient cohorts, including those with acute coronary syndromes.
Understanding the differences in stent types may help in choosing the best treatment option for patients with coronary artery disease.

Structured PICO

Does biodegradable polymer drug-eluting stents reduce MACE or TLR compared to durable polymer drug-eluting stents in patients with coronary artery disease?

Population

Patients with coronary artery disease (including an all-comer cohort and ACS-PCI patients)

Intervention

Biodegradable polymer drug-eluting stents (BP-DES)

Comparator

Durable polymer drug-eluting stents (DP-DES)

Outcome

Major Adverse Cardiovascular Events (MACE) and Target Lesion Revascularization (TLR)composite

Biodegradable polymer drug-eluting stents offer similar long-term safety to durable polymer stents but may reduce target lesion revascularization, particularly in ACS patients undergoing PCI.

Main Result

Absolute Event Rate: 0% vs 0%

Abstract

BP-DES and DP-DES show a similar long-term safety profile regarding MACE. BP-DES demonstrate a lower risk of TLR in the all-comer cohort, driven by reduced rates in ACS-PCI patients.

Perguntar à IA

Bookmark

View Full Paper